Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Aspirin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms DEA-LAA
- 15 Oct 2019 Planned End Date changed from 31 Aug 2020 to 31 Oct 2020.
- 15 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Oct 2020.
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.